Krystal Biotech, Inc. reached out to the FDA following promising early evidence.
2 reports, 2 independent
Updated Aug 22
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Krystal Biotech, Inc. reached out to the FDA following promising early evidence.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Krystal Biotech, Inc.
biotechnology company
Nothing else this week.
Related events
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Adam Craig reported positive results that could support FDA approval for a treatment.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- BioTech generated encouraging early data for MASH and POTS, and expects an FDA decision regarding cemdisiran next month.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
Coverage
Newest first; wire copies grouped- GlobeNewswireKrystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer PITTSBURGH, Aug. 21, 2025 (GLOBE N
- ZacksKRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook Krystal Biotech (KRYS) reported second-quarter 2025 earnings per share (EPS) of $1.29, which beat the Zacks Consensus Estimate of $1